202 related articles for article (PubMed ID: 9543458)
1. Resolution of azole-resistant oropharyngeal candidiasis after initiation of potent combination antiretroviral therapy.
Valdez H; Gripshover BM; Salata RA; Lederman MM
AIDS; 1998 Mar; 12(5):538. PubMed ID: 9543458
[No Abstract] [Full Text] [Related]
2. Reduction in oropharyngeal candidiasis following introduction of protease inhibitors.
Hood S; Bonington A; Evans J; Denning D
AIDS; 1998 Mar; 12(4):447-8. PubMed ID: 9520182
[No Abstract] [Full Text] [Related]
3. A randomized study of the use of fluconazole in continuous versus episodic therapy in patients with advanced HIV infection and a history of oropharyngeal candidiasis: AIDS Clinical Trials Group Study 323/Mycoses Study Group Study 40.
Goldman M; Cloud GA; Wade KD; Reboli AC; Fichtenbaum CJ; Hafner R; Sobel JD; Powderly WG; Patterson TF; Wheat LJ; Stein DK; Dismukes WE; Filler SG; ;
Clin Infect Dis; 2005 Nov; 41(10):1473-80. PubMed ID: 16231260
[TBL] [Abstract][Full Text] [Related]
4. Withdrawal of fluconazole suppressive therapy for thrush in patients responding to combination antiviral therapy including protease inhibitors.
Gripshover BM; Valdez H; Salata RA; Lederman MM
AIDS; 1998 Dec; 12(18):2513-4. PubMed ID: 9875599
[No Abstract] [Full Text] [Related]
5. Candidiasis at ICAAC.
Barr D; Smart T
GMHC Treat Issues; 1995 Oct; 9(10):13. PubMed ID: 11362914
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of melaleuca oral solution for the treatment of fluconazole refractory oral candidiasis in AIDS patients.
Jandourek A; Vaishampayan JK; Vazquez JA
AIDS; 1998 Jun; 12(9):1033-7. PubMed ID: 9662200
[TBL] [Abstract][Full Text] [Related]
7. [For oral candidiasis and co. Fluconazole remains in the forefront].
MMW Fortschr Med; 2004 Apr; 146 Spec No 1():90. PubMed ID: 15373066
[No Abstract] [Full Text] [Related]
8. Geneva reports have implications for dental providers.
Ritchie J
Fac Notes (New Orleans La); 1998; 10(5):11-2. PubMed ID: 11365832
[TBL] [Abstract][Full Text] [Related]
9. [Oral amphotericin B inefficacy in the treatment of fluconazole++ resistant oropharyngeal candidiasis in HIV-positive patients].
Laguna F; Valencia E; Polo R; Moreno V; González-Lahoz JM
Rev Clin Esp; 1996 Dec; 196(12):878-9. PubMed ID: 9132869
[No Abstract] [Full Text] [Related]
10. Human immunodeficiency virus disease: natural history and management.
Depaola LG
Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2000 Sep; 90(3):266-70. PubMed ID: 10982944
[No Abstract] [Full Text] [Related]
11. Effect of prolonged HAART on oral colonization with Candida and candidiasis.
Yang YL; Lo HJ; Hung CC; Li Y
BMC Infect Dis; 2006 Jan; 6():8. PubMed ID: 16423306
[TBL] [Abstract][Full Text] [Related]
12. [Progressive resistance to fluconazole in a patient with HIV infection and recurrent oropharyngeal candidiasis].
Corzo Delgado JE; Lozano de León F; Aretio Najarro R; Martín Mazuelos E
Med Clin (Barc); 1994 Nov; 103(16):639. PubMed ID: 7996928
[No Abstract] [Full Text] [Related]
13. Fluconazole prophylaxis in HIV disease, revisited.
Bozzette SA
Clin Infect Dis; 2005 Nov; 41(10):1481-2. PubMed ID: 16231261
[No Abstract] [Full Text] [Related]
14. The diagnosis and treatment of candidiasis: current therapeutic options.
Filler SG
AIDS Patient Care STDS; 1997 Feb; 11 Suppl 1():S10-4; discussion S15. PubMed ID: 11361745
[No Abstract] [Full Text] [Related]
15. Detection of fungal organisms in saliva from HIV-infected children: a preliminary cytologic analysis.
Hicks MJ; Carter AB; Rossmann SN; Demmler GJ; Simon CL; Cron SG; Flaitz CM; Shearer WT; Kline MW
Pediatr Dent; 1998; 20(3):162-8. PubMed ID: 9635310
[TBL] [Abstract][Full Text] [Related]
16. Assessment of therapeutic response of oropharyngeal and esophageal candidiasis in AIDS with use of a new clinical scoring system: studies with D0870.
Hood SV; Hollis S; Percy M; Atkinson G; Williams K; Denning DW
Clin Infect Dis; 1999 Mar; 28(3):587-96. PubMed ID: 10194083
[TBL] [Abstract][Full Text] [Related]
17. Effect of highly active antiretroviral therapy on recurrent oropharyngeal candidiasis in HIV-infected patients.
Revankar SG; Sanche SE; Dib OP; Caceres M; Patterson TF
AIDS; 1998 Dec; 12(18):2511-3. PubMed ID: 9875598
[No Abstract] [Full Text] [Related]
18. Single-dose fluconazole versus standard 2-week therapy for oropharyngeal candidiasis in HIV-infected patients: a randomized, double-blind, double-dummy trial.
Hamza OJ; Matee MI; Brüggemann RJ; Moshi MJ; Simon EN; Mugusi F; Mikx FH; van der Lee HA; Verweij PE; van der Ven AJ
Clin Infect Dis; 2008 Nov; 47(10):1270-6. PubMed ID: 18840077
[TBL] [Abstract][Full Text] [Related]
19. Oropharyngeal candidiasis in patients with human immunodeficiency virus: correlation of clinical outcome with in vitro resistance, serum azole levels, and immunosuppression.
Walmsley S; King S; McGeer A; Ye Y; Richardson S
Clin Infect Dis; 2001 Jun; 32(11):1554-61. PubMed ID: 11340526
[TBL] [Abstract][Full Text] [Related]
20. The treatment of oral candidiasis in a cohort of South African HIV/AIDS patients.
Blignaut E; Botes ME; Nieman HL
SADJ; 1999 Dec; 54(12):605-8. PubMed ID: 16892568
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
